Windtree Therapeutics

community rating (0 votes): 


A biotechnology company focused on developing novel KL4 surfactant therapies for respiratory diseases and other potential applications.



No Reviews Yet

Be the first to review one of our webinars!

Upcoming Webinars

Previous Webinars

Windtree Therapeutics Inc (WINT)
Windtree Therapeutics, Inc. is advancing late-stage interventions for acute cardiovascular disorders to treat patients in moments of crisis. Using new scientific and clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with an ability to activate SERCA2a, with lead candidate, istaroxime, being developed as a first-in-class treatment for cardiogenic shock. Windtree's heart failure platform includes follow-on oral pre-clinical SERCA2a activator assets as well. Included in Windtree's portfolio is rostafuroxin, a novel precision drug product targeting the treatment resistant hypertension disease state for patients with certain genetic profiles.
11/16/2023 6:45 PM